4-chloro-6-oxo-1-phenyl-1,6-dihydropyridazine-3-carboxylic acid | 339030-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-chloro-6-oxo-1-phenyl-1,6-dihydropyridazine-3-carboxylic acid
• 英文别名: 4-chloro-6-oxo-1-phenylpyridazine-3-carboxylic acid
• CAS: 339030-73-8
• 化学式: C₁₁H₇ClN₂O₃
• 分子量: 250.641
• InChiKey: YTIMCBIDXRPLPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-6-oxo-1-phenyl-1,6-dihydropyridazine-3-carboxylic acid 在 钯 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 6-oxo-1-phenyl-1,6-dihydro-pyridazine-3-carboxylic acid
  参考文献：
  名称：

  Beta-secretase modulators and methods of use

  摘要：

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，该化合物具有通式I，其中A、B、R3、R4、R5、i和j在此定义。本发明还包括包含一种或多种通式I化合物的药物组合物，以及使用这些化合物的方法，包括通过向受体注射通式I化合物或包含它们的组合物来治疗AD和相关疾病。本发明还包括通式II和III的进一步实施例，以及制备本发明化合物的中间体和过程。

  公开号：

  US08163766B2

文献信息

• [EN] NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE PYRIDAZINONE ET PYRIDONE
  申请人：BIOTIE THERAPIES CORP

  公开号：WO2012120195A1

  公开（公告）日：2012-09-13

  The invention relates to pyridazinone and pyridone com- pounds having formula (I) or (I'), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1 / R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned com- pounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  这项发明涉及具有化学式（I）或（I'）的吡啶二酮和吡啶酮化合物，以及其药学上可接受的盐、水合物和溶剂化合物（I）其中R1 / R4和X和X3如权利要求所定义。该发明还涉及它们作为含铜胺氧化酶的抑制剂的用途。本发明还涉及上述化合物的制备，以及包含上述化合物、药学上可接受的盐、水合物或溶剂化合物作为活性成分的药物组合物。
• Beta-Secretase modulators and methods of use
  申请人：Amgen Inc.

  公开号：US07872009B2

  公开（公告）日：2011-01-18

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新型化合物类别，可用于调节β-秘鲁酶酶活性和治疗β-秘鲁酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。在一种实施例中，该化合物具有一般式I，其中A、B、R3、R4、R5、i和j在此定义。本发明还包括包括一种或多种I式化合物的制药组合物，使用这些化合物的方法，包括通过将I式化合物或包括它们的组合物用于治疗AD和相关疾病来给予受试者。本发明还包括II式和III式的进一步实施例，中间体和制备本发明化合物的有用过程。
• BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：Albrecht Brian K.

  公开号：US20110118250A1

  公开（公告）日：2011-05-19

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，所述化合物具有一般式I，其中A、B、R3、R4、R5、i和j在此被定义。本发明还包括包括一种或多种式I化合物的制药组合物，以及使用这些化合物的方法，包括将式I化合物或包含它们的组合物用于治疗AD和相关疾病，通过将式I化合物或包含它们的组合物用于给予受试者的方法。本发明还包括式II和III的进一步实施例，以及用于制备本发明化合物的中间体和方法。
• NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS
  申请人：Pihlavisto Marjo

  公开号：US20140024648A1

  公开（公告）日：2014-01-23

  The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R 1 /R 4 and X and X 3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明涉及具有式（I）或（I'）的吡啶并咪唑酮和吡啶酮化合物，以及其药学上可接受的盐、水合物和溶剂化物（I）其中R1/R4和X和X3如权利要求中所定义。本发明进一步涉及它们作为含铜胺氧化酶的抑制剂的用途。本发明还涉及制备上述化合物以及包含作为活性成分的制药组合物，其中活性成分是上述化合物之一或多个，其药学上可接受的盐、水合物或溶剂化物。
• PYRIDAZINONE AND PYRIDONE COMPOUNDS
  申请人：BIOTIE THERAPIES CORPORATION

  公开号：US20160244414A1

  公开（公告）日：2016-08-25

  The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R 1 /R 4 and X and X 3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明涉及具有式（I）或（I'）的吡啶嗪和吡啶酮化合物，以及其药学上可接受的盐，水合物和溶剂化物，其中R1 / R4和X和X3如权利要求所定义。本发明进一步涉及它们作为含铜胺氧化酶的抑制剂的用途。本发明还涉及前述化合物的制备以及包含作为活性成分的制药组合物之一或多个前述化合物，药学上可接受的盐，水合物或溶剂化物。